Safinamide mesylate is under clinical development by Zambon Co and currently in Phase II for Drug-Induced Dyskinesia. According to GlobalData, Phase II drugs for Drug-Induced Dyskinesia does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Safinamide mesylate LoA Report. Buy the report here.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Safinamide mesylate overview

Safinamide mesylate (Xadago,Equfina ) is an alpha-aminoamide derivative act as add-on therapy to dopamine agonists or levodopa. It is formulated as film-coated tablets for oral route of administration. Xadago is indicated in the treatment of idiopathic Parkinson's disease (PD) or for mid-to late-stage fluctuating patients as add-on therapy to a stable dose of Levodopa (L-dopa) alone or in combination with other PD medicinal products.

It is under development for the treatment of multiple system atrophy (MSA), levodopa-induced dyskinesia and Parkinson's disease in Israel and Mexico. It was also under development for the treatment of restless legs syndrome and amyotrophic lateral sclerosis.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Zambon Co overview

Zambon Co (Zambon) manufactures pharmaceutical and fine chemical products. The company offers pharmaceutical products for the respiratory, central nervous system, pain management, women’s healthcare, and rare diseases and specialties, including Parkinson’s disease and cystic fibrosis. It also provides active pharmaceutical ingredients (API), intermediates and custom synthesis services. The company has manufacturing plants in Cadempino, Switzerland; Haikou, China; Vicenza, Italy; and Barueri, Brazil. It distributes products directly and also through a network of distributors across North America, Latin America, Europe, the Middle East, and Africa, and Asia. Zambon is headquartered in Milano, Italy.

For a complete picture of Safinamide mesylate’s drug-specific PTSR and LoA scores, buy the report here.